Results for:(113 found)
Feb 3, 2012 12:12PM on Top StocksBy MSN Money Partner

Goldman upgrades Eastman Chemical and downgrades Vertex Pharmaceuticals.

Feb 1, 2012 12:27PM on Top StocksBy MoneyShow.com

This monthly scan is helpful for identifying which stocks may be too risky for new buying. It also turns up a pair of compelling 'buy' candidates.

Jan 27, 2012 1:00PM on Top StocksBy MoneyShow.com

Some of the biggest and highest-yielding drug stocks are declining near attractive buy levels.

Jan 26, 2012 5:33PM on Top StocksBy InvestorPlace

These picks fit the bill in a sector with great long-term prospects.

Jan 24, 2012 2:57PM on Top StocksBy MSN Money Partner

However you slice it, J&J's prospect of earnings growth looks bleak as economic and competitive 'headwinds' continue.

Jan 24, 2012 11:33AM on Top StocksBy MSN Money Partner

Zynga is initiated with 'outperform,' and Deutsche Banks is downgraded to 'neutral.'

Jan 9, 2012 5:05PM on Top StocksBy MSN Money Partner

Bristol joins Gilead, Merck, Vertex, Roche and others in a race to treat hepatitis c.

Tags: BMYMRK
Jan 9, 2012 11:30AM on Top StocksBy MSN Money Partner

Travelers is upgraded to 'conviction buy' at Goldman, while Akamai is downgraded to 'sell' at Citigroup.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More